ClinConnect ClinConnect Logo
Search / Trial NCT01694563

ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation

Launched by ATRICURE, INC. · Sep 24, 2012

Trial Information

Current as of April 29, 2025

Completed

Keywords

Atrial Fibrillation

ClinConnect Summary

This prospective, open label, multi-center, observational, single arm registry is designed to monitor the AtriCure Synergy Ablation System continued safety and efficacy during the peri-procedural and long-term phase during commercial use in patients being treated for non-paroxysmal forms of atrial fibrillation who are undergoing a concomitant open, on-pump cardiac surgical procedure.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \> or equal to 18 years of age
  • * History of non-paroxysmal form of Atrial Fibrillation (AF) as defined by the Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society Consensus Statement:
  • Persistent AF shall be defined as continuous AF that is sustained beyond seven days. Episodes of AF in which a decision is made to electrically or pharmacologically cardiovert the patient after greater than or equal to 48 hours of AF but prior to 7 days, should also be classified as persistent AF episodes.
  • Longstanding persistent AF shall be defined as continuous AF of greater than 12 months duration. The performance of a successful cardioversion (sinus rhythm \>30 seconds) within 12 months of an ablation procedure with documented early recurrence of AF with 30 days should not alter the classification of AF as longstanding persistent.
  • Subject is scheduled to undergo elective open cardiac surgical procedure(s) to be performed on cardiopulmonary bypass for one or more of the following: Coronary Artery Bypass Grafting, Mitral valve repair or replacement, Aortic valve repair or replacement, Tricuspid valve repair or replacement. In conjunction with these procedure patent foramen ovale (PFO) or atrial septal defect (ASD) repair are allowed.
  • The patient (or their legally authorized representative) agrees to participate in this study by singing the Institutional Review Board (IRB) approved informed consent form.
  • Willing and able to return for scheduled follow up visits.
  • Exclusion Criteria:
  • Stand along AF without indication(s) for concomitant cardiac surgery.
  • Need for emergent cardiac surgery (i.e., cardiogenic shock).
  • Preoperative need for an intra-aortic balloon pump or intravenous inotropes.
  • Pregnancy or desire to get pregnant for the duration of the study concomitant surgical procedure through the thirty six (36) month follow up period).
  • Enrolled in another clinical trial that could confound the results of this study.

About Atricure, Inc.

AtriCure, Inc. is a leading medical device company focused on developing innovative solutions for the treatment of atrial fibrillation and other cardiac conditions. With a commitment to advancing cardiac surgery and improving patient outcomes, AtriCure specializes in technologies that address the complexities of heart rhythm disorders. The company's portfolio includes a range of devices and therapies designed to facilitate atrial fibrillation management and enhance surgical techniques. Through rigorous clinical trials and a dedication to research, AtriCure aims to provide healthcare professionals with effective tools to optimize patient care in the field of electrophysiology and beyond.

Locations

Ann Arbor, Michigan, United States

Cleveland, Ohio, United States

Saint Petersburg, Florida, United States

Portland, Maine, United States

Royal Oak, Michigan, United States

Toledo, Ohio, United States

Traverse City, Michigan, United States

Norfolk, Virginia, United States

San Diego, California, United States

Grand Forks, North Dakota, United States

Pittsburgh, Pennsylvania, United States

Memphis, Tennessee, United States

Saint Louis, Missouri, United States

Hartford, Connecticut, United States

Portland, Oregon, United States

Saint Louis, Missouri, United States

Charlotte, North Carolina, United States

Richmond, Virginia, United States

Seattle, Washington, United States

Birmingham, Alabama, United States

Paterson, New Jersey, United States

Los Angeles, California, United States

Los Angeles, California, United States

Salt Lake City, Utah, United States

Wausau, Wisconsin, United States

Charlotte, North Carolina, United States

Grand Rapids, Michigan, United States

Philadelphia, Pennsylvania, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Lincoln, Nebraska, United States

Fort Myers, Florida, United States

Saint Petersburg, Florida, United States

Lansing, Michigan, United States

Scottsdale, Arizona, United States

West Hollywood, California, United States

Gainesville, Florida, United States

Tampa, Florida, United States

Evanston, Illinois, United States

Springfield, Illinois, United States

Indianapolis, Indiana, United States

Indianapolis, Indiana, United States

West Roxbury, Massachusetts, United States

Minneapolis, Minnesota, United States

Asheville, North Carolina, United States

Greensboro, North Carolina, United States

Cincinnati, Ohio, United States

Oklahoma City, Oklahoma, United States

Harrisburg, Pennsylvania, United States

Dallas, Texas, United States

Patients applied

0 patients applied

Trial Officials

Patrick McCarthy, MD

Study Chair

Chief, Division of Cardiac Surgery, Northwestern University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials